| 2025-12-11 |
详情>>
内部人交易：
Bancel Stephane股份增加688073.00股
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本39067.95万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-5.15美元,归母净利润-19.96亿美元,同比去年增长18.23%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘前发布财报
|
| 2025-10-15 |
股东大会：
将于2025-11-12召开股东大会
会议内容 ▼▲
- 1.To approve a one-time stock option exchange program for non-Executive Committee employees of Moderna (the Option Exchange Proposal);
2.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Exchange Proposal (the Adjournment Proposal).
|
| 2025-08-01 |
详情>>
业绩披露：
2025年中报每股收益-4.64美元,归母净利润-17.96亿美元,同比去年增长26.81%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益-2.52美元,归母净利润-9.71亿美元,同比去年增长17.36%
|
| 2025-03-11 |
股东大会：
将于2025-04-30召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors, each to serve for a three-year term expiring at the 2028 annual meeting of shareholders;
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025;
4.To transact such other business as may be properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-02-21 |
详情>>
业绩披露：
2024年年报每股收益-9.28美元,归母净利润-35.61亿美元,同比去年增长24.46%
|
| 2025-02-21 |
详情>>
业绩披露：
2022年年报每股收益21.26美元,归母净利润83.62亿美元,同比去年增长-31.47%
|
| 2025-02-14 |
复牌提示：
2025-02-14 09:35:33 停牌，复牌日期 2025-02-14 09:40:33
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-6.37美元,归母净利润-24.41亿美元,同比去年增长50.50%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益-3.39美元,归母净利润-13.01亿美元,同比去年增长-122.22%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-6.41美元,归母净利润-24.54亿美元,同比去年增长-88.62%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-3.07美元,归母净利润-11.75亿美元,同比去年增长-1587.34%
|
| 2024-03-21 |
股东大会：
将于2024-05-06召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors, each to serve for a three-year term expiring at the 2027 annual meeting of shareholders;
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024;
4.To approve a management proposal to amend our Certificate of Incorporation to provide shareholders the right to call a special meeting;
5.To approve a management proposal to amend our Certificate of Incorporation to reflect new Delaware law provisions allowing for officer exculpation;
6.To transact such other business as may be properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-02-23 |
详情>>
业绩披露：
2023年年报每股收益-12.33美元,归母净利润-47.14亿美元,同比去年增长-156.37%
|
| 2023-11-03 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-12.89美元,归母净利润-49.31亿美元,同比去年增长-171.49%
|
| 2023-03-15 |
股东大会：
将于2023-05-03召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders;
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023;
4.To vote on a shareholder proposal requesting a report on the feasibility of transferring intellectual property;
5.To transact such other business as may be properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-03-09 |
股东大会：
将于2022-04-28召开股东大会
会议内容 ▼▲
- 1.Elect three Class I directors, each for a three-year term
2.Approve, on a non-binding, advisory basis, the compensation of our named executive officers
3.Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2022
4.Shareholder Proposal - Report on Feasibility of Transferring Intellectual Property
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-10 |
股东大会：
将于2021-04-28召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors, each to serve for a three-year term expiring at the 2024 annual meeting of stockholders;
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021;
4.To transact such other business as may be properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-03-16 |
股东大会：
将于2020-04-29召开股东大会
会议内容 ▼▲
- 1.To elect three of our Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2023 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation, or removal;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020;
3.To cast a non-binding, advisory vote to approve the compensation of our named executive officers;
4.To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers;
5.To transact such other business as may be properly brought before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-05-15 |
股东大会：
将于2019-06-27召开股东大会
会议内容 ▼▲
- 1.To elect three of our Class I director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2022 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation, or removal;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019;
3.To transact such other business as may be properly brought before the Annual Meeting or any adjournment or postponement thereof.
|